Gastroenterology and internal medicine research institute

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight	Body Weight, Crohn disease, Digestive System Diseases, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, nutritional disorder, obesity disorder, overnutrition	Recruiting	Phase 3	2026-10-07		NCT06937099

Clinical trials